Universe Pharmaceuticals Inc (UPC)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.59M
Last updated: Nov 17, 2026 at 8:19 AM ET
Universe Pharmaceuticals Inc (UPC) Financials: Revenue, Profit and Cash Flow
Universe Pharmaceuticals reported revenue of $17.86M for the fiscal year ended Sep 30, 2025, down 22.4% from the year before. That year, net income was -$3.67M with a net margin of -20.6%, operating cash flow was -$5.05M and free cash flow was -$5.40M. The quarter ended Jun 30, 2026 had revenue of $9.04M and net income of -$1.55M.
Revenue and Margins
The operating margin was -16.3% in the fiscal year ended Sep 2025. Over the 7 years to Sep 2025, revenue fell from $28.51M, a compound annual decline of 6.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $17.86M | -22.4% | 35.3% | -16.3% | -20.6% |
| Sep 2024 | $23.02M | -28.7% | 26.4% | -34.8% | -37.9% |
| Sep 2023 | $32.31M | -19.5% | 31.9% | -10.9% | -19.1% |
| Sep 2022 | $40.14M | -16.3% | 54.5% | -17.5% | -21.8% |
| Sep 2021 | $47.98M | +56.3% | 52.8% | 28.3% | 23.6% |
| Sep 2020 | $30.70M | -7.6% | 45.9% | 33.4% | 24.6% |
| Sep 2019 | $33.23M | +16.5% | 40.3% | 29.4% | 22.7% |
| Sep 2018 | $28.51M | N/A | 47.0% | 33.9% | 26.7% |
Income Statement
In the fiscal year ended Sep 2025, the net loss narrowed from the year before.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.86M | $23.02M | $32.31M | $40.14M | $47.98M | $30.70M | $33.23M | $28.51M |
| Cost of revenue | $11.56M | $16.95M | $21.99M | $18.25M | $22.66M | $16.61M | $19.82M | $15.11M |
| Gross profit | $6.30M | $6.07M | $10.32M | $21.89M | $25.33M | $14.09M | $13.41M | $13.41M |
| Research and development | $671.76K | $3.60M | $4.86M | $7.62M | $5.47M | $583.13K | $618.44K | $789.38K |
| Operating income | -$2.92M | -$8.02M | -$3.53M | -$7.02M | $13.59M | $10.25M | $9.75M | $9.66M |
| Net income | -$3.67M | -$8.73M | -$6.16M | -$8.74M | $11.32M | $7.56M | $7.55M | $7.60M |
| EBITDA | N/A | -$7.36M | -$3.18M | -$6.40M | $14.20M | $10.61M | $10.17M | $10.11M |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Mar 2025 | Jun 2024 | Dec 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.04M | $8.71M | $9.15M | $12.88M | $13.84M | $18.47M | N/A | $15.94M | N/A | $24.20M | $24.20M | $23.69M |
| Gross profit | $3.23M | $3.14M | $3.16M | $3.24M | $4.06M | $6.01M | N/A | $8.05M | N/A | $13.63M | $13.63M | $13.26M |
| Operating income | -$1.50M | -$589.16K | -$2.33M | -$1.74M | -$3.68M | $149.25K | N/A | -$10.14M | N/A | $2.70M | $2.70M | $4.01M |
| Net income | -$1.55M | -$387.30K | -$3.28M | -$13.10M | -$5.45M | -$715.43K | N/A | -$10.47M | N/A | $1.73M | $1.73M | $4.17M |
Balance Sheet
As of Sep 2025, cash and equivalents exceeded short-term debt of $9.26M by $24.34M.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $69.30M | $67.95M | $53.29M | $59.54M | $70.14M | $28.80M | $17.84M | $28.08M |
| Current assets | $53.60M | $51.64M | $36.81M | $41.51M | $50.48M | $22.84M | $12.23M | $21.96M |
| Cash and equivalents | $33.59M | $29.50M | $5.29M | $5.71M | $8.08M | $10.06M | $3.18M | $6.19M |
| Total liabilities | $13.17M | $22.45M | $13.75M | $13.10M | $11.21M | $8.00M | $5.45M | $18.40M |
| Short-term debt | $9.26M | N/A | $5.48M | $3.94M | $4.33M | $2.65M | $2.52M | $2.62M |
| Long-term debt | N/A | $2.14M | N/A | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $56.13M | $45.50M | $39.53M | $46.44M | $58.93M | $20.80M | $12.38M | $9.68M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $71.47M | $71.47M | $69.30M | $69.30M | $80.67M | $67.95M | $49.43M | $49.43M | $53.29M | $41.72M | $70.37M | $70.37M |
| Total liabilities | $15.82M | $15.82M | $13.17M | $13.17M | $25.48M | $22.45M | $22.69M | $22.69M | $13.75M | $13.75M | $23.24M | $23.24M |
| Cash and equivalents | $27.56M | $27.56M | $33.59M | $33.59M | $47.27M | $29.50M | $8.86M | $8.86M | $5.29M | $5.29M | $12.95M | $12.95M |
| Shareholder equity | $55.65M | $55.65M | $56.13M | $56.13M | $55.18M | $45.50M | $26.74M | $26.74M | $39.53M | $27.97M | $47.13M | $47.13M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Sep 2025.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.05M | -$9.51M | $1.12M | -$1.31M | -$2.06M | $6.12M | $13.20M | $4.46M |
| Capital expenditures | $347.19K | $363.09K | $44.17K | $93.70K | $13.53M | $51.80K | $86.32K | $145.09K |
| Free cash flow | -$5.40M | -$9.87M | $1.08M | -$1.41M | -$15.59M | $6.06M | $13.12M | $4.31M |
| Dividends paid | N/A | N/A | N/A | $0 | $0 | $0 | $16.00M | $3.06M |
| Investing cash flow | -$341.81K | N/A | -$44.17K | -$3.91M | -$27.06M | -$51.80K | -$86.03K | -$145.09K |
| Financing cash flow | $9.73M | $33.95M | -$1.39M | $3.32M | $26.58M | $470.14K | -$16.00M | -$4.91M |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Mar 2025 | Jun 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.30M | -$7.61M | $2.56M | -$2.43M | -$3.64M | N/A | $4.80M | $2.40M | -$7.90M |
| Capital expenditures | $311.03K | $169.99K | $96.78K | $67.66K | $43.52K | $0 | $646 | $323 | $38.07K |
| Free cash flow | -$4.61M | -$7.78M | $2.46M | -$2.50M | -$3.68M | N/A | $4.80M | $2.40M | -$7.94M |
Frequently Asked Questions About UPC
What is Universe Pharmaceuticals' annual revenue?
Universe Pharmaceuticals reported revenue of $17.86M for the fiscal year ended Sep 30, 2025.
How fast is Universe Pharmaceuticals' revenue growing?
Revenue was down 22.4% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -23.7%.
Is Universe Pharmaceuticals profitable?
No. Universe Pharmaceuticals reported net income of -$3.67M for the fiscal year ended Sep 30, 2025, with a net margin of -20.6%.
How much free cash flow does UPC generate?
For the fiscal year ended Sep 30, 2025, operating cash flow of -$5.05M minus capital expenditures of $347.19K produced free cash flow of -$5.40M.
How much debt does Universe Pharmaceuticals have?
The balance sheet dated Sep 30, 2025 reported short-term debt of $9.26M and cash and equivalents of $33.59M.
UPC pages: Overview, Financials